Ongoing clinical trials are exploring the use of PSMA tracers for both diagnostic and theranostic applications in malignant brain tumors (ClinicalTrials.gov ID: NCT05798273, NCT06241391, NCT06209567). Here, FOLH1 is linked to brain cancer.